Rubius Therapeutics Inc (NASDAQ:RUBY) has announced updated data from the ongoing monotherapy Phase 1 arm of the Phase 1/2 trial of RTX-240 in advanced solid tumors.
- Data were shared at the American Association for Cancer Research Annual Meeting.
- Nine dose cohorts (n=34) were completed in the monotherapy solid tumor arm.
- Disease control was observed in 10 patients (1 partial response, 2 unconfirmed partial responses and 7 with stable disease), 9 of whom had experienced disease progression on prior anti-PD-1/anti-PD-L1 therapy.
- There were three best responses of partial response (PR) in non-small cell lung cancer (NSCLC), anal cancer, and uveal melanoma patients:
- Stable disease was observed in 5 patients, including 3 with metastatic NSCLC and 2 with renal cell carcinoma (RCC) across the 3e10 cohorts.
- The Company has selected a Phase 2 dose of 5e10 cells administered every 3 weeks. This dose will be further explored in the combination expansion cohort of NSCLC and RCC patients.
- Rubius also announced final results from the Phase 1 arm of monotherapy RTX-240 in relapsed/refractory AML.
- Seventeen patients were enrolled across four dose levels. No dose-limiting toxicities were observed, and there were 3 treatment-related Grade 3/4 adverse events.
- There were no investigator-reported immune-related AEs.
- Five patients had SD greater than 3 months, and 1 patient had a significant blast count reduction (53% to 6%).
- Price Action: RUBY shares are down 44.4% at $3.26 during the market session on the last check Friday.
